Injectable Drug Delivery Companies

The global injectable drug delivery market is projected to reach USD 1,034.78 billion by 2030 from USD 690.23 billion in 2025, at a CAGR of 8.4% during the forecast period. The injectable drug delivery devices market is expected to increase from USD 256.3 billion in 2025 to USD 373.3 billion by 2030, at a CAGR of 7.8% during this period. On the other hand, the injectable drug delivery formulations market is anticipated to grow from USD 434.0 billion in 2025 to USD 661.1 billion by 2030, at a CAGR of 8.8% throughout the forecast period.

The injectable drug delivery market is driven by several key factors. One of the primary drivers is the focus on developing innovative biologics. There has been an increase in the use of these medications due to the rising prevalence of chronic diseases, including cardiovascular diseases, cancer, diabetes, and obesity. The parenteral route of drug administration, which involves injectables, is often preferred over oral drug delivery because it allows for the rapid onset of action as the medication directly enters the bloodstream.

Additionally, the development of injectable formulations utilizing nanoparticles, microparticles, and liposomes for targeted drug delivery further contributes to market growth. The advancement of drug delivery devices, such as prefilled syringes, cartridges, autoinjectors, pen injectors, and wearable injectors, has also improved patient compliance by offering privacy and autonomy to patients.

To know about the assumptions considered for the study download the pdf brochure

The injectable drug delivery market faces several challenges. Patients often experience fear of needles and the discomfort associated with frequent injections, which can lead to lower compliance rates. Additionally, injectable medications tend to be more expensive to manufacture and store compared to other forms of medication. They may also require specialized storage conditions, such as temperature-controlled facilities.

The key players in the injectable drug delivery market include Johnson & Johnson Services, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Cardinal Health (US), BD (US), Baxter International Inc. (US), B. Braun SE (Germany), and Terumo Corporation (Japan).

In 2024, Merck & Co., Inc. (US) acquired Eye Biotech Limited (UK) to develop an intravitreal injection for treating diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

In 2024, BD (US) and Ypsomed (Switzerland) announced a partnership to innovate in self-injection solutions and high-viscosity biologic drugs, utilizing the BD Neopak XtraFlow Glass Prefillable Syringe combined with Ypsomed’s YpsoMate 2.25 autoinjector platform.

Cardinal Health (US) is a global supplier of healthcare products and services in over 30 countries. The company has two main segments: Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution. It provides services to hospitals, pharmacies, laboratories, and home-care settings. In addition to drug distribution, the Pharmaceutical division offers specialized services such as logistics management, nuclear pharmacy, and specialty pharmacy. The Healthcare division offers a wide range of products, including safety syringes (under the Magellan and Monoject brands), laboratory supplies, and anesthesia devices. Cardinal Health's OptiFreight Logistics service manages over 22 million shipments annually, optimizing supply chain performance. The company is dedicated to innovation, operational excellence, and improving patient care outcomes through its extensive network and advanced analytical capabilities.

BD (US) is a global company that supplies medical devices, diagnostic equipment, and interventional treatments in over 190 countries. The organization has three main business divisions: Interventional, Life Sciences, and Medical. The Medical division focuses on drug management and delivery systems, including items like IV catheters, syringes, and needles. The Interventional division addresses critical care, urology, and surgical needs, while the Life Sciences division specializes in diagnostics and biosciences. BD is also well-known for its commitment to innovation and has several subsidiaries in Germany, Canada, and the US. Due to its advancements in patient care and contributions to health technology, Fortune ranked the company among the top 25% of the most innovative US companies in 2025.

Johnson & Johnson Services, Inc. (US) is a major healthcare company that operates through two main business segments: MedTech and Innovative Medicine. The Innovative Medicine segment offers treatments for infectious diseases, immunology, oncology, and various other conditions, distributing products through wholesalers, hospitals, and retailers. Key injectable drugs in this segment include REMICADE, SIMPONI, STELARA, TREMFYA, and DARZALEX, with the latter generating approximately USD 3 billion in quarterly sales. The company operates through more than 265 subsidiaries, such as Janssen Pharmaceuticals and Actelion Pharmaceuticals, and has a presence in over 60 countries.

F. Hoffmann-La Roche Ltd. (Switzerland) is a leading biotech company specializing in in vitro diagnostics and pharmaceutical products for rare diseases, immunology, ophthalmology, and cancer. Its key injectable products include Hemlibra, Ocrevus, Phesgo, and Vabysmo. Roche collaborates with over 250 global partners and conducts pharmaceutical research and development through its subsidiaries, Genentech (US) and Chugai (Japan). The company operates in over 150 countries, partnering with organizations such as Spark Therapeutics and Roche Diagnostics Corporation.

Market Ranking

The injectable drug delivery market is categorized into two segments: devices and formulations. The top five companies in the injectable drug delivery devices segment are Cardinal Health (US), BD (US), Baxter (US), B. Braun SE (Germany), and Terumo Corporation (Japan).

Cardinal Health (US) utilizes data analytics, artificial intelligence (AI), and predictive modeling, focusing on innovation and strategic partnerships to maintain a strong market presence. BD (US) is notable for its extensive range of products, including medical devices, diagnostics, and bioscience solutions, as well as its strategic partnerships. Baxter (US) bolsters its position through strategic alliances and acquisitions aimed at enhancing its digital health capabilities. B. Braun SE has strengthened its market presence by expanding manufacturing facilities and strategic acquisitions. Meanwhile, Terumo Corporation (Japan) is benefiting from its growth in markets such as India and China, alongside its investments in ePRISM technology.

The top five companies in the injectable drug delivery formulations market are Johnson & Johnson Services, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (US), Merck & Co., Inc. (US), and Novartis AG (Switzerland).

Johnson & Johnson Services, Inc. strengthens its market position by expanding its portfolio with new products. F. Hoffmann-La Roche Ltd. focuses on key therapeutic areas that significantly impact global health, leveraging its worldwide presence through strategic partnerships and acquisitions. Pfizer Inc. is dedicated to developing innovative products and technologies, continually enhancing its research and development programs. Merck & Co., Inc. boosts its market presence through acquisitions and collaborations. Meanwhile, Novartis AG leverages its strong market position by concentrating on core therapeutic areas and expanding its portfolio to include advanced technologies, such as radioligand therapy (RLT) programs.

Related Reports:

Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) & Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com